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Open acAbstract Background: Multiple studies suggest better efﬁcacy of chemotherapy in invasive
ductal breast carcinomas (IDC) than invasive lobular breast carcinomas (ILC). However, data
on efﬁcacy of adjuvant endocrine therapy regimens and histological subtypes are sparse. This
study assessed endocrine therapy efﬁcacy in IDC and ILC. The inﬂuence of semi-quantitative
oestrogen receptor (ER) expression by Allred score was also investigated.
Methods: Dutch and Belgian patients enrolled in the Tamoxifen Exemestane Adjuvant
Multinational (TEAM) trial were randomized to exemestane (25 mg daily) alone or following
tamoxifen (20 mg daily) for 5 years. Inclusion was restricted to IDC and ILC patients. Histo-
logical subtype was assessed locally; ER expression was centrally reviewed according to Allred
score (ER-poor (<7; n = 235); ER-rich (P7; n = 1789)). Primary end-point was relapse-free
survival (RFS), which was the time from randomization to disease relapse.26
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298 W. van de Water et al. / European Journal of Cancer 49 (2013) 297–304Findings: Overall, 2140 (82%) IDC and 463 (18%) ILC patients were included. RFS was sim-
ilar for both endocrine treatment regimens in IDC (hazard ratio (HR) for exemestane was 0.83
(95%conﬁdence interval (CI) 0.67–1.03)), and ILC (HR 0.69 (95%CI 0.45–1.06)). Irrespective
of histological subtype, patients with ER-rich Allred scores allocated to exemestane alone had
an improved RFS (multivariable HR 0.71 (95%CI 0.56–0.89)). In contrast, patients with ER-
poor Allred scores allocated to exemestane had a worse RFS (multivariable HR 2.33 (95%CI
1.32–4.11)). Signiﬁcant effect modiﬁcation by ER-Allred score was conﬁrmed (multivariable
p = 0.003).
Interpretation: Efﬁcacy of endocrine therapy regimens was similar for IDC and ILC. How-
ever, ER-rich patients showed superior efﬁcacy to upfront exemestane, while ER-poor
patients had better outcomes with sequential therapy, irrespective of histological subtype,
emphasising the relevance of quantiﬁcation of ER expression.
Funding: The Dutch/Belgian TEAM trial is supported by an unrestricted research grant from
Pﬁzer. The sponsors have in no way inﬂuenced the design and conduct of the study, collection,
management, analysis and interpretation of the data and preparation, review or approval of
the manuscript.
 2012 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction
Treatment decisions in breast cancer therapy are
increasingly dependent on a growing number of molec-
ular tumour characteristics, consequently paving the
way towards individual targeted treatment regimens.
Invasive ductal breast carcinoma (IDC), is by far the
most common type of breast cancer.1 The second largest
group, found in 10–15% of all female breast cancers is
invasive lobular breast carcinoma (ILC); ILC patients
tend to be older, and tumours are frequently larger in
size, oestrogen and progesterone receptor (ER and
PR) positive and human epidermal growth factor recep-
tor 2 (HER2), p53 and epidermal growth factor receptor
(EGFR) negative when compared to IDC.2 ILC is also
frequently associated with higher ER expression than
IDC.3,4
With regard to endocrine therapy, several reports
have endorsed the association between higher levels of
ER expression and the prediction of eﬃcacy of endo-
crine therapy.5–7 However, the association between his-
tological subtype and eﬃcacy of adjuvant endocrine
therapy is seldom addressed, as reports have frequently
combined IDC and ILC in these eﬃcacy analyses. In
1987, Smith et al. demonstrated similar survival after
endocrine treatment with tamoxifen or ovarian ablation
in IDC and ILC.8 Another study investigated pathologic
parameters and adjuvant tamoxifen response in IDC
and ILC. But interaction analyses did not show signiﬁ-
cant diﬀerences in response to tamoxifen in IDC com-
pared with ILC, and inclusion was restricted to
premenopausal patients of which less than 2% were trea-
ted with adjuvant chemotherapy.4 A study by Rakha
and colleagues, on the other hand, demonstrated a bet-
ter response to various forms of endocrine therapy (ET)
(tamoxifen, aromatase inhibitors, ovarian ablation or
high-dose progestins) in ILC than IDC.9 Thus, data
comparing treatment response between the two majorsubtypes are scarce and inconsistent, and lack data on
quantitative hormone receptor expression.
Upfront treatment with aromatase inhibitors (AI) or
sequential therapy with tamoxifen followed by an AI
for a total of 5 years is currently the most widely applied
endocrine treatment regimen for postmenopausal hor-
mone receptor positive (HR+) early breast cancer
patients.10 However, recommendations on prescribing
adjuvant endocrine therapy make no distinction between
IDC and ILC or quantitative hormone receptor expres-
sion.11 In a recent report of the Tamoxifen Exemestane
Adjuvant Multinational (TEAM) trial by Bartlett and
colleagues, a non-signiﬁcant beneﬁt for exemestane com-
pared with tamoxifen was established in patients with
high ER expression based on Allred scores, although fol-
low-up was limited to 2.75 years.12 The TransATAC
(Arimidex, Tamoxifen Alone or in Combination) trial
also demonstrated a signiﬁcant improvement in time to
relapse with respect to increasing ER expression in
patients treated with anastrozole, while this could not
be established for tamoxifen-treated patients.13 In ER
poor patients, recurrence rates at 2 years of follow up
were lower for those allocated tamoxifen versus anas-
trozole, but by about 5 years, rates were similar. No
analyses by histological subtype were performed.
Current evidence is too inconsistent to establish a
preferential treatment for histological subtypes in clini-
cal practice. The reported variability in evidence regard-
ing outcome after ET in IDC and ILC may be due to
relatively small numbers of included ILC cases, as well
as the retrospective nature of many studies previously
reported. As ILC is more often ER-positive and fre-
quently associated with stronger ER expression than
IDC, we investigated whether the histological subtype
would translate to diﬀerential eﬃcacies of two endocrine
treatment regimens in Dutch and Belgian patients
included in the TEAM trial on the basis of quantitative
ER expression using the Allred score.12,14
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2.1. International TEAM trial design
The TEAM trial is a randomized, adjuvant, phase 3,
multinational, open label study conducted in postmeno-
pausal women with oestrogen and/or progesterone
receptor positive tumours. Patients were randomized
to receive either exemestane 25 mg once-daily for 5 years
or tamoxifen 20 mg once-daily for 2.5–3 years, followed
by exemestane 25 mg once-daily for 2.5–2 years, for a
total of 5 years. Participants were enrolled in Belgium,
the Netherlands, United Kingdom, Ireland, United
States of America, Japan, Greece, Germany and France.
Eligibility criteria have been published in earlier
reports.10,15 In short, postmenopausal patients with his-
tologically conﬁrmed breast adenocarcinoma, who com-
pleted local therapy with curative intent, i.e. without
evidence of metastatic disease, were eligible. Appropri-
ate approvals from the ethical committees were
obtained. All patients provided written informed con-
sent, and additional consent was obtained from patients
in the tamoxifen group for the switch to exemestane.2.2. Design of the current study
Inclusion in the present study was restricted to Dutch
and Belgian patients, due to the central review of tumour
characteristics in this population (n = 3167). Patients
with a lobular or ductal tumour subtype (n = 2603) were
eligible for inclusion. The remaining patients had inva-
sive mixed (n = 134, 4.2%), unspeciﬁed (n = 24, 0.8%)
and unknown (n = 406, 12.8%) subtypes. The database
was locked on 23rd February 2011. Data collection
was performed locally on speciﬁc study case report
forms, and transferred to the central data center in Lei-
den, the Netherlands. Histological subtype was deter-
mined by the local pathologist conform international
criteria as described in the literature.16 The use of E-cad-
herin was not used routinely. Auditing of pathology
reports was performed centrally in Leiden. ER and PR
expression was reassessed and quantiﬁed centrally in
Edinburgh, United Kingdom. Detailed information is
provided in a recent report by Bartlett and colleagues.12
Oestrogen and progesterone receptor expression were
evaluated as binary categories according to the Allred
score, with PR and ER cutoﬀ at the median in line with
those reported by Bartlett et al. (PR-poor 64 versus PR-
rich P5; ER-poor 66 versus ER-rich P7).12 Patients
with unknown ER Allred scores (n = 108) were not
included in the survival analyses by Allred score, irre-
spective of their PR score. To assess the robustness of
the ﬁndings, additional analyses were performed using
the ER histoscore.12 ER histoscore was dichotomized
at the median. ER receptor expression and histoscore
could be determined for 2461 patients (94.5%).2.3. End-points
The primary end-point of the current study was
relapse free survival (RFS), which was deﬁned as the
time from randomization to the earliest documentation
of disease relapse. Disease relapse was deﬁned as tumour
recurrence (locoregional or distant), ipsilateral or con-
tralateral breast cancer. Ductal carcinoma in situ was
not considered a relapse.102.4. Statistical analysis
Statistical analyses were performed using SPSS 17.0
(SPSS, Chicago, IL) and R statistical package. To com-
pare diﬀerences in proportions between patients with
lobular and ductal breast tumours, Pearson chi-square
test and the Independent sample t-test were used. Kap-
lan–Meier curves were plotted and Cox proportional
hazard models were used to assess survival diﬀerences
with respect to treatment arm. Survival analyses were
stratiﬁed by histological subtype and ER Allred score.
Interaction terms between treatment arm and histologi-
cal subtype, and between treatment arm and ER Allred
score respectively, were included in the Cox proportional
hazard model to test for the presence of eﬀect modiﬁca-
tion. Multivariable survival analyses by histological type
were adjusted for age, histological grade (Bloom Rich-
ardson grade 1;2;3), T-stage (1;2;3,4), nodal stage (nega-
tive; positive), ER Allred score (ER-rich; ER-poor), PR
Allred score (PR-rich; PR-poor), HER2 status (positive;
negative), most extensive surgery (mastectomy; wide
local excision), radiotherapy (yes; no), and chemother-
apy (yes; no). Multivariable analyses by ER Allred score
were adjusted for age, histological grade (Bloom Rich-
ardson grade 1;2;3), T-stage (1;2;3,4), nodal stage (nega-
tive; positive), PR Allred score (PR-rich; PR-poor),
HER2 status (positive; negative), most extensive surgery
(mastectomy; wide local excision), radiotherapy (yes;
no), and chemotherapy (yes; no). To evaluate the interac-
tion between randomized treatment and ER expression
in more detail, we performed a sliding window subpopu-
lation treatment eﬀect pattern plot (STEPP) analysis.17,18
All statistical tests were two-sided. A p-value of <0.05
was considered statistically signiﬁcant.3. Results
Overall, 2603 patients from the Netherlands and Bel-
gium who were included in the multinational TEAM
trial, were included in this analysis, of which 2140
(82%) presented with IDC and 463 (18%) with ILC.
Baseline characteristics of the included patients are
shown by histological subtype in Table 1. Patients with
a lobular subtype were signiﬁcantly older (p = 0.004),
had larger tumours (p < 0.001) and more frequently
were node positive (p = 0.034) and had an unknown
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patients with ILC more frequently underwent a mastec-
tomy (p < 0.001) and received less chemotherapy
(p = 0.024). No diﬀerences were observed for other ther-
apies applied.
At database lock, there were 338 (16%) relapses in
patients with IDC and 83 (18%) in patients with ILC.
Five-year RFS was 86% for IDC and 83% for ILC
(IDC functioned as a reference, ILC univariate hazard
ratio (HR) 1.15 (95% conﬁdence interval (CI) 0.90–Table 1
Patient characteristics by histological subtype. The bold values are those ch
and lobular patients.
Ductal (n = 2140)
n %
Age (mean, SD) 65.0 9.2
Grade (BR)
Well (G1) 318 14.9
Moderate (G2) 897 41.9
Poor (G3, G4) 848 39.6
Unknown 77 3.6
T stage
1 1041 48.6
2 1002 46.8
3, 4 96 4.5
Unknown 0 0.0
N stage
Negative 662 30.9
Positive 1475 69.0
Unknown 3 0.1
ER Allred score*
Low 235 11.0
High 1789 83.6
Unknown 116 5.4
PR Allred score**
Low 503 25.1
High 1498 74.9
Unknown 139 6.5
HER2
Positive 276 12.9
Negative 1719 80.3
Unknown 145 6.8
Most extensive surgery
Mastectomy 1104 51.6
WLE 1036 48.4
Adjuvant radiotherapy
Yes 1348 63.0
No 789 36.9
Unknown 3 0.1
Adjuvant chemotherapy
Yes 698 32.6
No 1441 67.4
Randomization
Exemestane 1096 51.2
Sequential 1044 48.8
BR, Bloom Richardson; ER, estrogen receptor; PR, progesterone receptor
* Low: <7; High: P7.
** Low: <5; High: P5.1.46), p = 0.257; ILC multivariable HR 1.18 (95% CI
0.89–1.57), p = 0.257). Table 2 shows eﬃcacy analyses
stratiﬁed by histological subtypes. In patients with
IDC, RFS was not signiﬁcantly diﬀerent for either
treatment regimen (sequential therapy functioned as a
reference, univariate HR for exemestane: 0.83 (95%CI
0.67–1.03), p = 0.089; multivariable HR 0.90 (95%CI
0.72–1.13), p = 0.373). Comparable results were
observed in patients with ILC (univariate HR 0.69
(95%CI 0.45–1.06), p = 0.089; multivariable HR 0.61aracteristics that were statistically signiﬁcantly diﬀerent between ductal
Lobular (n = 463) p Value
n %
66.3 9.4 0.004
58 12.5 <0.001
236 51.0
88 19.0
81 17.5
<0.001
133 28.7
251 54.2
77 16.6
2 0.4
0.034
120 25.9
343 74.1
0 0.0
0.724
56 12.1
380 82.1
27 5.8
0.062
88 20.8
336 79.2
39 8.4
<0.001
21 4.5
394 85.1
48 10.4
<0.001
332 71.7
131 28.3
0.397
282 60.9
181 39.1
0 0.0
0.024
126 27.2
337 72.8
0.152
220 47.5
243 52.5
; WLE, wide local excision.
Table 2
Relapse free survival by treatment regimen, stratiﬁed by histological subtype.
5 years survival Univariate HR (95%CI) p Value Multivariable** HR (95% CI) p Value
IDC 0.089 0.373
Tam! Exe* 84% 1 (reference) 1 (reference)
Exemestane 87% 0.83 (0.67–1.03) 0.90 (0.72–1.13)
ILC 0.089 0.053
Tam! Exe 80% 1 (reference) 1 (reference)
Exemestane 86% 0.69 (0.45–1.06) 0.61 (0.37–1.01)
IDC, invasive ductal breast carcinoma; ILC, invasive lobular breast carcinoma; HR, hazard ratio; CI, conﬁdence interval.
* Tamoxifen followed by exemestane.
** HR adjusted for age, histological grade, T stage, nodal stage, estrogen receptor (ER) Allred score, progesterone receptor (PR) Allred score,
HER2 status, most extensive surgery, radiotherapy, and chemotherapy.
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whether eﬃcacy analyses were modiﬁed by histological
subtype, we included an interaction term between ran-
domization and histological subtype. No signiﬁcant
interaction was observed (multivariable p = 0.148).
The number of patients having an ER-rich tumour
was 1789 (89.5%) in IDC patients, and 380 (87.6%) in
ILC patients (p = 0.234). Median ER Allred scores were
similar in IDC and ILC patients (7 versus 7), mean ER
Allred score was slightly lower in IDC patients (6.89 ver-
sus 6.98, p = 0.042). Due to the fact that a previous
study showed better RFS in patients with ER-rich All-
red scores, and because patients with ILC more often
present with ER-positive disease, survival by ER Allred
score was assessed in patients with ductal and lobular
subtypes separately.
For both histological subtypes, ER-rich Allred scores
showed superior outcomes for upfront exemestane in
both univariate and multivariable analyses (Web
Table 1). In contrast, in both IDC and ILC patients with
ER-poor Allred scores, those who were allocated exe-
mestane had a worse relapse free survival. No signiﬁcant
eﬀect modiﬁcation by histological subtype was observed
for ER-rich Allred scores (p = 0.201) and ER-poor All-
red scores (p = 0.799).
Because of the absence of eﬀect modiﬁcation, survival
analyses were repeated for all patients. Cumulative inci-
dence of breast cancer relapse by treatment regimen for
both patients with ER-rich and ER-poor tumours is
shown in Fig. 1 (Web Table 2). As shown in Table 3,
patients with ER-rich Allred scores and allocated
5 years of exemestane showed a more than 30%
improved RFS when compared to patients allocated
sequential treatment, which was conﬁrmed in multivari-
able analyses (HR for exemestane: 0.72 (95%CI 0.57–
0.90), p = 0.004). In contrast, ER-poor Allred scores in
combination with allocation to exemestane mono-
therapy was associated with a worse RFS, which was
even more pronounced after multivariable analyses
(HR for exemestane: 1.85 (95%CI 1.11–3.09),
p = 0.019). ER Allred score was a signiﬁcant eﬀect mod-
iﬁer of endocrine therapy eﬃcacy in all patients (multi-
variable p for interaction = 0.003). Similar analyseswere performed for PR Allred score, but no signiﬁcant
eﬀect modiﬁcation was observed (p for
interaction = 0.137).
To assess the robustness of the ﬁndings, additional
analyses were performed using the ER histoscore instead
of the ER Allred score. ER histoscore was dichotomized
at the median, which resulted in 1231 patients with ER-
rich tumours and 1230 patients with ER-poor tumours.
Results are shown in Web Table 3. In both univariate
and multivariable analyses, patients with a high histo-
score derived a signiﬁcant beneﬁt from exemestane
monotherapy (multivariable HR for exemestane was
0.56 (95%CI 0.39–0.80), p = 0.001). No diﬀerence was
observed for patients with a low histoscore (multivari-
able HR for exemestane was 1.04 (95%CI 0.80–1.34),
p = 0.779). Nevertheless, signiﬁcant eﬀect modiﬁcation
by histoscore (p = 0.005) was observed. Additionally, a
sliding window STEPP analysis was performed
(Fig. 2), which showed a dose-response relation. More-
over, only those patients with the lowest ER histoscores
derived beneﬁt from a sequential therapy regimen, while
with increasing histoscore, the beneﬁt of exemestane
monotherapy increased. Lastly, as ILC patients received
less chemotherapy, sensitivity analyses were also per-
formed restricted to patients without prior chemother-
apy. These analyses revealed similar results (data not
shown).
4. Discussion
This study showed no preferential beneﬁt from endo-
crine therapy based on histological subtype in patients
with either IDC or ILC. However, a major ﬁnding of
the present study was that eﬃcacy of endocrine therapy
regimens was modiﬁed by ER Allred scores: an
improved RFS was demonstrated in ER-rich patients
when treated with 5 years of exemestane, whereas ER-
poor patients beneﬁted more from the sequential treat-
ment strategy.
Several analyses were performed to assess sensitivity
of the used variables and robustness of our ﬁndings.
First, survival analyses were repeated with ER histo-
score instead of ER Allred score, which revealed
ER rich
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ysis was performed, which showed a dose-response rela-
tion between increasing ER histoscore and beneﬁt of
exemestane monotherapy. Lastly, analyses were
restricted to patients without prior chemotherapy, which
did not alter the results.
Despite the numerous diﬀerences between IDC and
ILC, histological subtype did not modify the eﬃcacy
of treatment regimen. As literature suggests diﬀerent dis-
tributions of ER Allred scores for IDC and ILC
patients,3,4 survival analyses by Allred score for both
IDC and ILC separately were performed. Again, similar
eﬀects in both IDC and ILC patients were observed, in
which higher ER Allred scores were predictive of a bet-
ter response to exemestane monotherapy, whereas aTable 3
Relapse free survival by treatment regimen, stratiﬁed by estrogen receptor
5 years survival Univariate HR (95% CI)
ER-rich
Tam! Exe* 80% 1 (reference)
Exemestane 73% 0.69 (0.56-0.86)
ER-poor
Tam! Exe 82% 1 (reference)
Exemestane 74% 1.66 (1.05–2.63)
HR, hazard ratio; CI, conﬁdence interval.
* Tamoxifen followed by exemestane.
** HR adjusted for age, histological subtype, histological grade, T stage, no
extensive surgery, radiotherapy and chemotherapy. ER-rich was deﬁned assequential treatment regimen was preferred in patients
with lower ER Allred scores. These ﬁndings support
the supposition of at least a similar eﬃcacy of endocrine
treatment in IDC and ILC. Of note, a prior publication
by Pestalozzi et al. revealed changes in survival advan-
tage for IDC and ILC over a 25-year period; up to
6 years, there is a survival beneﬁt for ILC, after which
the advantage changes to IDC.19 It is therefore impor-
tant to interpret our results in the context of longer-term
ﬁndings.
Regardless of histological subtype, a signiﬁcant eﬀect
modiﬁcation by ER Allred score was ascertained.
Patients with ER-rich tumours responded better to
5 years of exemestane, and patients with ER-poor
tumours were better oﬀ with the sequential treatment
regimen. It is tempting to speculate on the mechanisms
which may explain the results observed. Although not
the case in all patients, ER expression can decrease dur-
ing tamoxifen treatment, also one of the mechanisms
that contribute to reduced tolerability to endocrine(ER) Allred score.
p Value Multivariable** HR (95% CI) p Value
0.001 0.004
1 (reference)
0.72 (0.57-0.90)
0.031 0.019
1 (reference)
1.85 (1.11–3.09)
dal stage, progesterone receptor (PR) Allred score, HER2 status, most
an Allred score of 66; ER-poor was deﬁned as an Allred score ofP7.
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more rapid exhaustion of ER expression leads to an
improved response to a new mechanism that counters
the eﬀect of oestrogens on tumour growth, namely
through the inhibition of aromatase. Therefore, in ER-
poor tumours one can argue that these more readily
develop endocrine resistance than ER-rich tumours,
and thus the mechanism of switching therapy is more
relevant than the therapy itself.
A recent report by Bartlett and colleagues in the inter-
national TEAM data suggested a beneﬁcial eﬀect of exe-
mestane for ER-rich patients.12 However, in contrast to
the present investigation, no signiﬁcant treatment eﬀect
modiﬁcation by ER Allred score was observed. This
may be explained by the restriction to the two major his-
tological subtypes in the current study. Second, the pres-
ent ﬁndings are based on the Dutch and Belgian TEAM
participants only, who may display slightly diﬀerent
characteristics than the combined international data.15
However, as nearly one third of the patients included
in the international study are of Dutch/Belgian origin,
this is not likely to have a major inﬂuence on our ﬁnd-
ings. Third, the analyses by Bartlett and colleagues were
limited to 2.75 years of follow-up, whereas the median
follow-up of the current study was 5.2 years.
Data are conﬂicting on the topic of prognostic value
of quantitative hormone receptor expression. Previ-
ously, Mauriac and colleagues described prognostic risk
factors that are associated with disease relapse, based on
ﬁndings in the Breast International Group (BIG) 1-98
trial.22 In these analyses, a beneﬁcial eﬀect of letrozole
versus tamoxifen was found in patients with poorer
prognoses (in terms of tumour burden and aggressive-
ness), regardless of the inclusion of quantitative ER
expression in the analysis.22 In the same cohort of
patients, Viale et al. found that patients with lower levels
of ER (<80%) had more beneﬁt of letrozole mono-
therapy than patients with higher levels of ER
(P80%),23 while this could not be established in another
report by Regan et al.24 In contrast, combined analyses
of the ABCSG 8 and ARNO 95 trials concluded that
treatment eﬃcacy with anastrozole improved with
increasing ER expression, while this was not the case
in tamoxifen-treated patients.25
While our results remain to be conﬁrmed in other
studies, there is reason to believe that the diﬀerential
response based on ER expression is of clinical relevance.
The importance of quantitative associations between
hormone receptor content and response to endocrine
therapy has been documented in the past, and several
semi-quantitative scoring systems have been proposed
in order to reduce the number of borderline cases of
ER-positive tumours. However, it is still infrequently
used to determine treatment regimen clinically.
A major strength of the present investigation is the
relatively large cohort of patients with ILC as well asthe randomized design of this study, which assures qual-
ity controlled data and an extended record of patient
and treatment characteristics. More importantly, the
centrally reviewed ER expression excluded variation
between pathology centres. Since histological subtype
was assessed locally, we can not exclude a potential bias
in the inclusion of our patients. Inclusion in the TEAM
study was restricted to ER-and/or PR-positive breast
tumours, therefore it was not possible to elaborate on
the proportion of ILC patients with ER-positive
tumours compared to IDC patients. It is known that
ILC patients more frequently present with ER-positive
tumours, which predicts a superior response to endo-
crine therapy.26–29 Although a signiﬁcant eﬀect modiﬁ-
cation by ER expression was observed, the sliding
window STEPP analysis indicated that only those
patients with very low ER expression may be better oﬀ
with a sequential treatment, whereas patients with very
high ER expression derive beneﬁt from exemestane
monotherapy. This is in line with the results of our
Cox regression analyses, in which the eﬀect in ER-rich
patients is more outspoken than in ER-poor patients.
The retrospective, unplanned nature of this analysis ren-
ders our investigation hypothesis generating, and these
results will need to be validated through further investi-
gation prospectively in order to deﬁne a possible ER
expression cutoﬀ for treatment preference.
There was no diﬀerence in eﬃcacy of endocrine treat-
ment between IDC and ILC, and therefore endocrine
therapy remains warranted in ILC patients. Instead,
the extent of ER positivity may be superior in predicting
treatment eﬃcacy than histological subtype. In other
words, our hypothesis was not conﬁrmed on the basis
of histological subtypes. Alternatively, an eﬀect modiﬁ-
cation for treatment modality by ER expression in both
subtypes was established. The semi-quantitative analysis
of ER expression in postmenopausal early breast cancer
patients may therefore be an important item in clinical
decision-making to determining the optimal therapeutic
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